The infectious agent responsible for transmissible spongiform encephalopathies, also known as prion diseases, (which include mad cow disease), is a protein known as the infectious prion (PrPi), which has no nucleic acid and which produces contagious neurodegenerative diseases in different species of animals.
The PrPi changes shape to that of an existing natural protein in the organism, the cellular prion (PrPc), but does not change its amino acid sequence. In certain circumstances, when the PrPi comes into contact with the original proteins, the proteins take on the shape of the in the infectious protein. Once this accumulates in the central nervous system, it destroys neural mass and makes the brain of affected animals take on a sponge form, which is where the term "spongiform diseases" comes from.
The researchers' work focuses on producing a vaccine that will provide an immune response that is as complete as possible, including both a humoral response (production of antibodies) and a cellular response (eliminating "infected" cells and activating the "memory", enabling the animal cells to continue responding to the infectious agent).
The main obstacle to achieving this objective is that the prions do not produce an immune response since the metabolism of the affected animal identifies it as one of its own antigens. The challenge, therefore, is to overcome the tolerance barrier, that is, that the animal's body produces an immune response to one of its antigens.
The researchers have achieved this objective using a DNA vaccine based on a plasmid (an extrachromosomal DNA molecule) that expresses the prion gene with a small sequence that acts as a transport signal to cellular compartments called lysosomes. Once the vaccination is administered, the prion quickly degrades in the lysosome, allowing a marked improvement in the presentation of the cells of the immune system and inducing a powerful antibody and cellular response.
The results of the research have shown that in vaccinated mice, and only in those vaccinated, there is a significant delay in the appearance of symptoms after the intracerebral infection produced by the infectious prion.
The group is continuing its research to further investigate new administration routes for the vaccine and to eliminate the side effects observed in vaccinated animals.
This work may also enable advances to be made in the development of reactive agents for the diagnosis of diseases produced by the prion that until now could only be achieved post mortem.
Octavi López Coronado | alfa
Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH
Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences